Security Investigation
Beta Bionics, Inc. (NasdaqGM: BBNX)
55 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.
According to the Complaint, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) the Company’s sole commercialized device, the iLet Bionic Pancreas insulin pump (“iLet”), employed an aggressive automated dosing algorithm that malfunctioned and delivered dangerously high levels of insulin, causing hypoglycemic events, including hundreds of life-threatening events requiring medical intervention and hospitalization; (ii) the Company had received thousands of related customer complaints that it failed to investigate or timely report to the U.S. Food and Drug Administration (“FDA”); (iii) the FDA Form 483 issued to the Company in June 2025 identified more than 18,000 unreported complaints and was not, as Defendants represented, limited to a minor difference in interpretation of which complaints were reportable; (iv) the Company had failed to implement meaningful corrective actions in response to the Form 483, resulting in an FDA warning letter concerning the Company’s quality management system, medical device reporting, and corrections and removals; and (v) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
If you invested in Beta Bionics and suffered a loss during the relevant time frame, you have until November 3, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. Beta Bionics investors should contact KSF Managing Partner Lewis Kahn toll-free at (877) 515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is Holtzman v. Beta Bionics, Inc. et al., 26-cv-09999.